Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 21252289)

1.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.

Minematsu T, Giacomini KM.

Mol Cancer Ther. 2011 Mar;10(3):531-9. doi: 10.1158/1535-7163.MCT-10-0731. Epub 2011 Jan 20.

2.

Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.

Müller F, König J, Hoier E, Mandery K, Fromm MF.

Biochem Pharmacol. 2013 Sep 15;86(6):808-15. doi: 10.1016/j.bcp.2013.07.008. Epub 2013 Jul 20.

PMID:
23876341
3.

Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).

Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y.

Toxicol Appl Pharmacol. 2013 Nov 15;273(1):100-9. doi: 10.1016/j.taap.2013.08.024. Epub 2013 Aug 31.

4.
5.

Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M.

PLoS One. 2011;6(7):e22163. doi: 10.1371/journal.pone.0022163. Epub 2011 Jul 14.

6.

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U.

Clin Pharmacokinet. 2011 Sep;50(9):551-603. doi: 10.2165/11593320-000000000-00000.

PMID:
21827214
7.

Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.

Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D.

Drug Metab Dispos. 2008 Aug;36(8):1616-23. doi: 10.1124/dmd.108.020826. Epub 2008 May 19.

8.

Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.

König J, Zolk O, Singer K, Hoffmann C, Fromm MF.

Br J Pharmacol. 2011 Jun;163(3):546-55. doi: 10.1111/j.1476-5381.2010.01052.x.

10.

Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.

Khurana V, Minocha M, Pal D, Mitra AK.

Drug Metabol Drug Interact. 2014;29(4):249-59. doi: 10.1515/dmdi-2014-0014.

11.

Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo.

Cheng Y, Martinez-Guerrero LJ, Wright SH, Kuester RK, Hooth MJ, Sipes IG.

Drug Metab Dispos. 2011 Sep;39(9):1755-61. doi: 10.1124/dmd.110.035865. Epub 2011 Jun 6.

12.

Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.

Motohashi H, Inui K.

AAPS J. 2013 Apr;15(2):581-8. doi: 10.1208/s12248-013-9465-7. Epub 2013 Feb 22. Review.

13.

Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X.

Antimicrob Agents Chemother. 2014;58(3):1294-301. doi: 10.1128/AAC.02049-13. Epub 2013 Dec 2.

14.

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.

Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB.

Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6.

15.

Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).

Kikuchi R, Lao Y, Bow DA, Chiou WJ, Andracki ME, Carr RA, Voorman RL, De Morais SM.

J Pharm Sci. 2013 Dec;102(12):4426-32. doi: 10.1002/jps.23737. Epub 2013 Oct 2.

PMID:
24122511
16.

Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.

Grottker J, Rosenberger A, Burckhardt G, Hagos Y.

Drug Metabol Drug Interact. 2011;26(4):181-9. doi: 10.1515/DMDI.2011.024. Epub 2011 Nov 7.

PMID:
22149660
17.

Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.

Nies AT, Koepsell H, Damme K, Schwab M.

Handb Exp Pharmacol. 2011;(201):105-67. doi: 10.1007/978-3-642-14541-4_3. Review.

PMID:
21103969
18.

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G, Sarkadi B.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):623-42. doi: 10.1517/17425255.2011.562892. Epub 2011 Mar 17. Review.

PMID:
21410427
19.

Organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages of gestation.

Ahmadimoghaddam D, Zemankova L, Nachtigal P, Dolezelova E, Neumanova Z, Cerveny L, Ceckova M, Kacerovský M, Micuda S, Staud F.

Biol Reprod. 2013 Mar 7;88(3):55. doi: 10.1095/biolreprod.112.105064. Print 2013 Mar.

20.

Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

Kido Y, Matsson P, Giacomini KM.

J Med Chem. 2011 Jul 14;54(13):4548-58. doi: 10.1021/jm2001629. Epub 2011 Jun 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk